Table 1.
Baseline demographics and disease characteristics
| Characteristics |
Integrated IXE PsA
N=1401 |
| Age, years, mean (SD) | 49.1 (11.9) |
| Sex, n (%) | |
| Male | 679 (48.5) |
| Female | 722 (51.5) |
| Race, n (%) | |
| White | 1278 (91.3) |
| Other | 122 (8.7) |
| BMI, kg/m2, mean (SD) | 30.0 (6.9) |
| Duration of symptoms, years, mean (SD) | 9.4 (8.6) |
| Previous PsA systemic therapy, n (%) | |
| Never used | 290 (20.7) |
| Non-biologic | 1040 (74.2) |
| Biologic | 338 (24.1) |
| Medical history, n (%) | |
| Herpes zoster | 19 (1.4) |
| Candida infections | 4 (0.3) |
| Latent tuberculosis | 35 (2.5) |
| Inflammatory bowel disease | 14 (1.0) |
BMI, body mass index; IXE, ixekizumab; N, number of patients in the analysis population; n, number of patients in each category; PsA, psoriatic arthritis.